Современная концепция лечения местно-распространённого рака прямой кишки: обзор литературы

Современная концепция лечения местно-распространённого рака прямой кишки: обзор литературы

Автор: Солодкий В.А., Кандакова Е.Ю., Ильин М.А., Мирзаханова И.С.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры

Статья в выпуске: 2 т.23, 2023 года.

Бесплатный доступ

С начала 80-х годов прошлого века мы стали свидетелями эволюции роли и места лучевой терапии в лечении рака прямой кишки. В настоящее время «золотым стандартом» лечения местно-распространенного рака прямой кишки (МРРПК) является мультимодальный подход, включающий в себя предоперационную системную противоопухолевую лекарственную терапию, химиолучевое лечение и хирургическое вмешательство. В данном обзоре мы попытались отразить развитие парадигм лечения МРРПК.Различные исследования комплексного лечения МРРПК последовательно демонстрировали эффективность дополнения хирургического лечения лучевой терапией. Роль адъювантной химиотерапии (АХТ) на основе опубликованных исследований остается спорной, в то время как применение тотальной неоадъювантной терапия (ТНТ) в мультимодальном подходе в лечении больных МРРПК способствовало снижению риска отдаленного метастазирования, увеличению частоты органосохраняющих операций. Учитывая тот факт, что возможности лечения МРРПК быстро меняются, клиницистам следует тщательно адаптировать стратегии лечения для каждого пациента.

Еще

Местно-распространенный рак прямой кишки (мррпк), тотальная неоадъювантная терапия, лучевая терапия, предоперационное лечение

Короткий адрес: https://sciup.org/149143493

IDR: 149143493

Список литературы Современная концепция лечения местно-распространённого рака прямой кишки: обзор литературы

  • Gollins S, Sebag-Montefiore D. Neoadjuvant Treatment Strategies for Locally Advanced Rectal Cancer. Clin Oncol (R Coll Radiol). 2016;28:146-151. doi: 10.1016/j.clon.2015.11.003.
  • Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:29-42. doi: 10.1016/S1470-2045(20)30555-6.
  • Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez-Nebout N, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22:702-715. doi: 10.1016/S1470-2045(21)00079-6.
  • Habr-Gama A, São Julião GP, Vailati BB, Sabbaga J, Aguilar PB, Fernandez LM, et al. Organ Preservation in cT2N0 Rectal Cancer After Neoadjuvant Chemoradiation Therapy: The Impact of Radiation Therapy Dose-escalation and Consolidation Chemotherapy. Ann Surg. 2019;269:102-107. doi: 10.1097/SLA.0000000000002447.
  • van der Valk MJM, Hilling DE, Bastiaannet E, Meershoek-Klein Kranenbarg E, Beets GL, Figueiredo NL, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018;391:2537-2545. doi: 10.1016/S0140-6736(18)31078-X.
  • Dossa F, Chesney TR, Acuna SA, Baxter NN. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2:501-513. doi: 10.1016/S2468-1253(17)30074-2.
  • Thomas PR, Lindblad AS. Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience. Radiother Oncol. 1988;13:245-252. doi: 10.1016/0167-8140(88)90219-8.
  • Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH, et al. Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst .2000;92:388-396. doi: 10.1093/jnci/92.5.388.
  • Swedish Rectal Cancer Trial; Cedermark B, Dahlberg M, Glimelius B, Påhlman L, Rutqvist LE, Wilking N. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997;336:980-987. doi: 10.1056/NEJM199704033361402.
  • MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457-460. doi: 10.1016/0140-6736(93)90207-W.
  • van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575-582. doi: 10.1016/S1470-2045(11)70097-3.
  • Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638-646. doi: 10.1056/NEJMoa010580.
  • Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-1740. doi: 10.1056/NEJMoa040694.
  • Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811-820. doi: 10.1016/S0140-6736(09)60484-0.
  • Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324:709-715. doi: 10.1056/NEJM199103143241101.
  • O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994;331:502-507. doi: 10.1056/NEJM199408253310803.
  • Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620-4625. doi: 10.1200/JCO.2006.06.7629.
  • Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184-90. doi: 10.1016/S1470-2045(13)70599-0.
  • Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, et al. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. JNCI J Natl Cancer Inst. 2015;107:248. doi: 10.1093/jnci/djv248.
  • Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Lafay I, Hennequin C, Etienne PL, et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol. 2012;30:4558-4565. doi: 10.1200/JCO.2012.42.8771.
  • Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773-2780. doi: 10.1200/JCO.2010.34.4911.
  • Schmoll HJ, Stein A, Van Cutsem E, Price T, Hofheinz RD, Nordlinger B, et al. Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. J Clin Oncol. 2021;39:17-29. doi: 10.1200/JCO.20.01740.
  • Rödel C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16:979-989. doi: 10.1016/S1470-2045(15)00159-X.
  • Gollins S, Sun Myint A, Haylock B, Wise M, Saunders M, Neupane R, et al. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes. J Clin Oncol. 2011;29:1042-1049. doi: 10.1200/JCO.2010.29.7697.
  • Willeke F, Horisberger K, Kraus-Tiefenbacher U, Wenz F, Leitner A, Hochhaus A, et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer. 2007;96:912-7. doi: 10.1038/sj.bjc.6603645.
  • Kalofonos HP, Bamias A, Koutras A, Papakostas P, Basdanis G, Samantas E, et al. A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study. Eur J Cancer. 2008;44:1693-700. doi: 10.1016/j.ejca.2008.05.025.
  • Sebag-Montefiore D, Adams R, Gollins S, Samuel LM, Glynne-Jones R, Harte R, et al. ARISTOTLE: A phase III trial comparing concurrent capecitabine with capecitabine and irinotecan (Ir) chemoradiation as preoperative treatment for MRI-defined locally advanced rectal cancer (LARC). J Clin Oncol. 2020;38:4101. doi: 10.1200/JCO.2020.38.15_suppl.4101.
  • Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30:1620-1627. doi: 10.1200/JCO.2011.39.6036.
  • Gollins S, West N, Sebag-Montefiore D, Myint AS, Saunders M, Susnerwala S, et al. Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. Br J Cancer. 2017;117:1286-1294. doi: 10.1038/bjc.2017.294.
  • Pinto C, Di Fabio F, Maiello E, Pini S, Latiano T, Aschele C, et al. Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). Ann Oncol. 2011;22:2424-2430. doi: 10.1093/annonc/mdq782.
  • Nogué M, Salud A, Vicente P, Arriví A, Roca JM, Losa F, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011;16:614-620. doi: 10.1634/theoncologist.2010-0285.
  • Masi G, Vivaldi C, Fornaro L, Lonardi S, Buccianti P, Sainato A, et al. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. Eur J Cancer. 2019;110:32-41. doi: 10.1016/j.ejca.2019.01.006.
  • Bujko K, Nowacki MP, Nasierowska-Guttmejer A, Michalski W, Bebenek M, Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93:1215-1223. doi: 10.1002/bjs.5506.
  • Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30:3827-33. doi: 10.1200/JCO.2012.42.9597.
  • Ciseł B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol. 2019;30:1298-1303. doi: 10.1093/annonc/mdz186.
  • Bujko K, Wyrwicz L, Rutkowski A, Malinowska M, Pietrzak L, Kryński J, et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol. 2016;27:834-842. doi: 10.1093/annonc/mdw062.
  • Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17:2396. doi: 10.1200/JCO.1999.17.8.2396.
  • Erlandsson J, Holm T, Pettersson D, Berglund Å, Cedermark B, Radu C, et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017;18:336-346. doi: 10.1016/S1470-2045(17)30086-4.
  • Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo PA, Varma MG, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16:957-966. doi: 10.1016/S1470-2045(15)00004-2.
  • Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, et al. Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6). J Clin Oncol. 2016;34:3773-3780. doi: 10.1200/JCO.2016.67.6049.
  • Fisher B, Wolmark N, Rockette H, Redmond C, Deutsch M, Wickerham DL, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst.1988;80:21-29. doi: 10.1093/jnci/80.1.21.
  • Breugom AJ, van Gijn W, Muller EW, Berglund Å, van den Broek CBM, Fokstuen T, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26:696-701. doi: 10.1093/annonc/mdu560.
  • Glynne-Jones R, Counsell N, Quirke P, Mortensen N, Maraveyas A, Meadows HM, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol. 2014;25:1356-1362. doi: 10.1093/annonc/mdu147.
  • Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:200-207. doi: 10.1016/S1470-2045(14)71199-4.
  • Petersen SH, Harling H, Kirkeby LT, Wille-Jørgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev. 2012;(3):CD004078. doi: 10.1002/14651858.CD004078.pub2.
  • Cionini L., Sainato A., De Paoli A., Osti MF, Lupattelli M, Vidali C, et al. Final results of randomized trial on adjuvant chemotherapy after preoperative chemora- diation in rectal cancer. Radiother Oncol. 2010;96(suppl 1):S113.
  • Martin ST, Heneghan HM, Winter DC. Systematic review and meta- analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg. 2012;99(7):918–928.
  • Zorcolo L, Rosman AS, Restivo A, Pisano M, Nigri GR, Fancellu A, Melis M. Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: A meta- analysis. Ann Surg Oncol. 2012;19(9):2822–2832. doi: 10.1245/s10434-011-2209-y.
  • Fernandez-Martos C, Garcia-Albeniz X, Pericay C, Maurel J, Aparicio J, Montagut C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†. Ann Oncol. 2015;26:1722-1728. doi: 10.1093/annonc/mdv223.
  • Rutten HJ, den Dulk M, Lemmens VE, van de Velde CJ, Marijnen CA. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol. 2008;9:494-501. doi: 10.1016/S1470-2045(08)70129-3.
  • Burbach JP, den Harder AM, Intven M, van Vulpen M, Verkooijen HM, Reerink O. Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis. Radiother Oncol. 2014;113:1-9. doi: 10.1016/j.radonc.2014.08.035.
  • MacGregor TP, Maughan TS, Sharma RA. Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now. J Clin Pathol. 2012;65:867-71. doi: 10.1136/jclinpath-2012-200958.
  • Rupinski M, Szczepkowski M, Malinowska M, Mroz A, Pietrzak L, Wyrwicz L, et al. Watch and wait policy after preoperative radiotherapy for rectal cancer; management of residual lesions that appear clinically benign. Eur J Surg Oncol. 2016;42:288-296. doi: 10.1016/j.ejso.2015.09.022 .
  • Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711-717; discussion 717-718. doi: 10.1097/01.sla.0000141194.27992.32.
  • Beard BW, Rao AR, Schumacher A, Attaluri V, McLemore L. Watchful Waiting after Clinical Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer. Int J Radiat Oncol. 2019;105:E161. doi: 10.1016/j.ijrobp.2019.06.2133.
  • Fernandez LM, São Julião GP, Figueiredo NL, Beets GL, van der Valk MJM, Bahadoer RR, et al. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. Lancet Oncol. 2021;22:43-50. doi: 10.1016/S1470-2045(20)30557-X.
  • Garcia-Aguilar J, Patil S, Kim JK, Yuval JB, Thompson H, Verheij F, et al. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. J Clin Oncol. 2020;38:4008. doi: 10.1200/JCO.2020.38.15_suppl.4008.
  • Joye I, Deroose CM, Vandecaveye V, Haustermans K. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. Radiother Oncol. 2014;113:158-165. doi: 10.1016/j.radonc.2014.11.026.
  • de Jong EA, ten Berge JC, Dwarkasing RS, Rijkers AP, van Eijck CH. The accuracy of MRI, endorectal ultrasonography, and computed tomography in predicting the response of locally advanced rectal cancer after preoperative therapy: A metaanalysis. Surgery. 2016;159:688-699. doi: 10.1016/j.surg.2015.10.019.
  • Glynne-Jones R, Hughes R. Complete Response after Chemoradiotherapy in Rectal Cancer (Watch-and-Wait): Have we Cracked the Code? Clin Oncol (R Coll Radiol). 2016;28:152-160. doi: 10.1016/j.clon.2015.10.011.
  • Smith FM, Wiland H, Mace A, Pai RK, Kalady MF. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2014;57:311-315. doi: 10.1097/DCR.0b013e3182a84eba.
Еще
Статья научная
SciUp 2024 © 2024 ©